

---

# doc. MUDr. Norbert Pauk, Ph.D.

---



<div class="skolitel"></div>  
Department of Pneumology 3FM CU and UHB  
<https://www.lf3.cuni.cz/3LF-1324.html>  
[www.bulovka.cz/pneumologie](http://www.bulovka.cz/pneumologie)

## Topic title

Pneumology

## Description of scientific activity

Our mainstay programs include the care of patients with lung cancer. We are the largest pneumo-oncology center, diseases associated with airway obstruction (we are the National Center for Severe Asthma led by Dr. Pauk), interstitial lung processes (we are the Center for Interstitial Lung Diseases incl. Dr. Pauk) and sleep-disordered breathing, and we are involved in indications for home non-invasive ventilation (our physicians are authors of national guidelines). We are joining a national initiative for bronchogenic cancer screening and COPD (chronic obstructive pulmonary disease). The Clinic closely cooperates with the Surgical Clinic of the 1st Faculty of Medicine, IPVZ, the Institute of Radiation Oncology of the 1st Faculty of Medicine and other departments of the Faculty Hospital Bulovka and also the Faculty Hospital Královské Vinohrady. The clinic cooperates in several lung disease registries (Lung Cancer - Lucas project, COPD and Cesar project - for difficult-to-treat asthma). We present the results of our work at a lot of national and international conferences and publications. Thus, our clinical research focuses on pneumooncology, severe asthma, interstitial lung diseases and COPD. I review articles for many journals.

## Selected publications

Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Stowasser S2, Nishioka Y3, White ES4, Cottin V5, Noth I6, Selman M7, Rohr KB2, Michael A8, Ittrich C9, Diefenbach C9, Jenkins RG10; Lancet Respir Med. 2019 Sep;7(9):771-779.

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. 2018 Dec 6;379(23):2220-2229NEJM

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. MC1, Cho BC2, Kim JH3, Mazières J4, Vansteenkiste J5, Lena H6, Corral Jaime J7, Gray JE8, Powderly J9, Chouaid C10, Bidoli P11, Wheatley-Price P12, Park K13, Soo RA14, Huang Y15, Wadsworth C16, Dennis PA15, Rizvi NA17; Lancet Oncol. 2018 Apr;19(4):521-536.

## Selected or ongoing grants/clinical studies

Clinical trials: lung cancer, interstitial lung diseases, COPD, asthma bronchiale

## PhD Students

Number of PhD students currently studying : 1

Number of defended students with year of defence: 2 (2013, 2014)

